- Home
- ETV vs MESO Comparison
ETV vs MESO Comparison
Compare ETV & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETV
- MESO
- Stock Information
- Founded
- ETV 2005
- MESO 2004
- Country
- ETV United States
- MESO Australia
- Employees
- ETV N/A
- MESO N/A
- Industry
- ETV Investment Managers
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ETV Finance
- MESO Health Care
- Exchange
- ETV Nasdaq
- MESO Nasdaq
- Market Cap
- ETV 1.7B
- MESO 2.0B
- IPO Year
- ETV N/A
- MESO N/A
- Fundamental
- Price
- ETV $13.92
- MESO $14.79
- Analyst Decision
- ETV
- MESO Buy
- Analyst Count
- ETV 0
- MESO 2
- Target Price
- ETV N/A
- MESO $24.00
- AVG Volume (30 Days)
- ETV 252.5K
- MESO 157.6K
- Earning Date
- ETV 01-01-0001
- MESO 08-28-2025
- Dividend Yield
- ETV 8.75%
- MESO N/A
- EPS Growth
- ETV N/A
- MESO N/A
- EPS
- ETV N/A
- MESO N/A
- Revenue
- ETV N/A
- MESO $17,198,000.00
- Revenue This Year
- ETV N/A
- MESO $440.77
- Revenue Next Year
- ETV N/A
- MESO $110.74
- P/E Ratio
- ETV N/A
- MESO N/A
- Revenue Growth
- ETV N/A
- MESO 191.39
- 52 Week Low
- ETV $11.05
- MESO $9.61
- 52 Week High
- ETV $13.50
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- ETV 36.51
- MESO 39.27
- Support Level
- ETV $14.02
- MESO $14.42
- Resistance Level
- ETV $14.46
- MESO $15.61
- Average True Range (ATR)
- ETV 0.17
- MESO 0.47
- MACD
- ETV -0.06
- MESO -0.09
- Stochastic Oscillator
- ETV 5.51
- MESO 24.20
About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.